September 01, 2025

Dana-Farber Research News 09.01.2025

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 - August 15.

Dana-Farber

August 22, 2025

Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy

In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estro...

The ASCO Post

August 22, 2025

Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods

In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre...

The ASCO Post

August 22, 2025

New Recommendations Released for Managing Aromatase Inhibitor–Induced Bone Loss

A group of experts from seven professional societies have published a joint position statement in the Journal of Bone Oncology on the management of aromatase inhibitor–associated bone loss as a guide ...

The ASCO Post

August 21, 2025

Treatment Rechallenge After Interstitial Lung Disease Related to T-DXd: Is It Safe?

Rechallenge with the HER2-directed antibody-drug conjugate after grade 1 interstitial lung disease appeared to be safe in a diverse real-world population, including many patients with breast cancer, a...

The ASCO Post

March 10, 2023

Four Leading UPMC/Pitt Scientists Receive Funding for Research in Breast Cancer

UMPC Hillman Cancer Center researchers receive significant funding from the Breast Cancer Research Foundation to support investigations aiming to improve cancer screening and enhance HER2 therapy.

The ASCO Post

January 25, 2023

SERENA-2 Trial: Camizestrant Improves Progression-Free Survival in Advanced Breast Cancer

The oral selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, as compared with fulvestrant, in previously treated postmenopausal women with advanced breast canc...

The ASCO Post

February 17, 2023

Association of Anthracycline Use With Risk of Congestive Heart Failure Among Patients Treated for Breast Cancer or Lymphoma

In a retrospective, population-based, case-control study reported in JAMA Network Open, Larsen et al found that patients receiving anthracyclines for breast cancer or lymphoma were at a significantly ...

The ASCO Post

February 06, 2023

WHO Launches New Roadmap on Breast Cancer

The World Health Organization (WHO) has released a new Global Breast Cancer Initiative Framework, providing a roadmap to attain targets to save 2.5 million lives from breast cancer by 2040. The new fr...

The ASCO Post